1. Home
  2. VRCA vs AMWL Comparison

VRCA vs AMWL Comparison

Compare VRCA & AMWL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Verrica Pharmaceuticals Inc.

VRCA

Verrica Pharmaceuticals Inc.

HOLD

Current Price

$5.54

Market Cap

107.5M

Sector

Health Care

ML Signal

HOLD

Logo American Well Corporation

AMWL

American Well Corporation

HOLD

Current Price

$12.91

Market Cap

91.2M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRCA
AMWL
Founded
2013
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Retail: Computer Software & Peripheral Equipment
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
107.5M
91.2M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
VRCA
AMWL
Price
$5.54
$12.91
Analyst Decision
Buy
Hold
Analyst Count
2
6
Target Price
$17.00
$7.40
AVG Volume (30 Days)
36.0K
105.5K
Earning Date
05-11-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.06
EPS
N/A
N/A
Revenue
$35,577,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$94.44
$4.24
P/E Ratio
N/A
N/A
Revenue Growth
370.22
N/A
52 Week Low
$3.28
$3.71
52 Week High
$9.82
$11.45

Technical Indicators

Market Signals
Indicator
VRCA
AMWL
Relative Strength Index (RSI) 40.43 79.74
Support Level $5.32 $8.25
Resistance Level $6.60 N/A
Average True Range (ATR) 0.47 0.78
MACD -0.07 0.31
Stochastic Oscillator 22.10 96.41

Price Performance

Historical Comparison
VRCA
AMWL

About VRCA Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.

About AMWL American Well Corporation

American Well Corp is an enterprise platform and software company digitally enabling hybrid care by offering payers and health systems a technology-enabled care platform. The Amwell Platform, its cloud-based enablement platform, digitally enables a scalable healthcare experience across all care settings by enabling critical services like virtual primary care, urgent care, clinical partner programs, scheduling visits, etc. Additionally, the healthcare providers can use the platform to access familiar workflows for taking notes, prescribing, referencing clinical treatment guidelines, and other related activities. The firm also offers various paid services, including licensed clinical staffing, implementation support, workflow design, etc, to help clients execute their hybrid care strategies.

Share on Social Networks: